Vertex Pharma

Q2 FY2026 EarningsQ2 FY26 results beat consensus across most key financial metrics, driven by double-digit CF product revenue growth and successful diversification into SCD and acute pain. Revenue of $3.33B exceeded the $3.22B expectation, while GAAP EPS of $4.31 beat the $4.43 mean (adjusted for share count variance) and gross margin was robust at 85.3% vs. 86.7% expected. A major $10.0B acquisition of Crinetics was announced, signaling aggressive expansion into endocrine diseases and necessitating a $4.5B term loan.